<DOC>
	<DOC>NCT00696709</DOC>
	<brief_summary>The purpose of the study is to see if an investigational vaccine for shingles is safe and well tolerated and brings about an acceptable antibody response.</brief_summary>
	<brief_title>A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Must be 50 to 59 years of age No fever on vaccination days Must have had chickenpox or lived in an area where the chickenpox virus is prevalent for 30 or more years Females of childbearing potential must use acceptable forms of birth control Prior history of shingles Prior receipt of any chickenpox or shingles vaccine Pregnant or breastfeeding Received or expect to receive a live virus vaccine (such as measles, mumps, rubella) from 4 weeks before the first visit through the last visit Received or expect to receive an inactivated vaccine (such as tetanus or pneumonia) from 7 days before the first visit through the last visit Received immunoglobulin or blood products Receiving treatment that may weaken the immune system Have an immune system disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Herpes Zoster (Shingles)</keyword>
</DOC>